^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
anti-CD7 CAR-T cell therapy
i
Other names: anti-CD7 CAR-T cell therapy, anti-CD7 CAR-T cells, anti-CD7 chimeric antigen receptor cell therapy
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Shanghai Yake Biotech
Drug class:
CD7-targeted CAR-T immunotherapy
Related drugs:
2ms
CD7 CAR-T Bridging to alloHSCT for Severe Aplastic Anemia (clinicaltrials.gov)
P1, N=30, Recruiting, Zhejiang University
New P1 trial
|
anti-CD7 CAR-T cell therapy
4ms
Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell in Patients With Relapsed/Refractory Acute Leukemia (clinicaltrials.gov)
P1/2, N=200, Recruiting, The General Hospital of Western Theater Command
New P1/2 trial • CAR T-Cell Therapy • IO biomarker
|
anti-CD7 CAR-T cell therapy
1year
Clinical Trial for the Safety and Efficacy of Anti-CD7 CAR-T Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy (clinicaltrials.gov)
P1, N=81, Recruiting, Zhejiang University | Phase classification: P1/2 --> P1 | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2022 --> Dec 2023
Phase classification • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
CD7 (CD7 Molecule)
|
anti-CD7 CAR-T cell therapy
over1year
CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases (clinicaltrials.gov)
P2, N=30, Recruiting, Zhejiang University
New P2 trial • IO biomarker
|
CD7 (CD7 Molecule)
|
anti-CD7 CAR-T cell therapy
almost2years
HIGH SAFETY AND EFFICACY OF ANTI-CD7 CAR-T CELLS IN TREATING RELAPSED OR REFRACTORY CD7+ ACUTE MYELOID LEUKEMIA: FIRST-IN-HUMAN PHASE I STUDY (EBMT 2023)
Patients with R/R AML underwent leukapheresis and a lymphodepletion chemotherapy with cyclophosphamide and fludarabine or etoposide before CAR-T cell infusion. In this first-in-human study of anti-CD7 CAR-T cells for R/R AML, anti-CD7 CAR-T cells exhibited promising efficacy with manageable toxicity profile. A phase II trial of anti-CD7 CAR-T cells in larger patient cohorts is needed.
Clinical • P1 data • CAR T-Cell Therapy • IO biomarker
|
FLT3 (Fms-related tyrosine kinase 3) • CD123 (Interleukin 3 Receptor Subunit Alpha) • CD33 (CD33 Molecule)
|
FLT3-ITD mutation
|
cyclophosphamide • etoposide IV • fludarabine IV • anti-CD7 CAR-T cell therapy
over2years
CD7 CHIMERIC ANTIGEN RECEPTOR T CELLS FOR ADULT PATIENTS WITH REFRACTORY AND RELAPSED T CELL MALIGNANCIES (EHA 2022)
Auto- or allo-CAR-T have similar efficacy and safety in the process, thus optimal solutions can be selected depending on their situations. CD7 CAR-T presents a potential therapeutic option for adults with R/R T cell malignancies, but the long-term prognosis remains to be observed and improved.
Clinical • CAR T-Cell Therapy • IO biomarker
|
CD19 (CD19 Molecule) • CD8 (cluster of differentiation 8) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD7 (CD7 Molecule)
|
anti-CD7 CAR-T cell therapy
over3years
Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial. (PubMed, J Clin Oncol)
Among 20 patients with r/r T-ALL enrolled in this trial, donor-derived CD7 CAR T cells exhibited efficient expansion and achieved a high complete remission rate with manageable safety profile. A multicenter, phase II trial of donor-derived CD7 CAR T cells is in progress (NCT04689659).
P1 data • Journal • CAR T-Cell Therapy
|
CD7 (CD7 Molecule)
|
anti-CD7 CAR-T cell therapy
4years
Clinical Trial for the Safety and Efficacy of Anti-CD7 CAR-T Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy (clinicaltrials.gov)
P1/2, N=108, Recruiting, Zhejiang University
Clinical • New P1/2 trial • CAR T-Cell Therapy
|
CD7 (CD7 Molecule)
|
anti-CD7 CAR-T cell therapy
Share via
